Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DHD79B
|
|||
| Drug Name |
SMER3
|
|||
| Synonyms |
67200-34-4; SMER 3; 9H-Indeno[1,2-e][1,2,5]oxadiazolo[3,4-b]pyrazin-9-one; 9H-Indeno[1,2-b][1,2,5]oxadiazolo[3,4-E]pyrazin-9-one; SMER-3; C11H4N4O2; LSM-42773; 9H-Indeno-[1,2-e]-[1,2,5]-oxadiazolo-[3,4-b]-pyrazin-9-one; indeno[2,3-b]1,2,5-oxadiazolo[3,4-e]pyrazin-5-one; 2-Oxa-1,3,4,10-tetraaza-cyclopenta[b]fluoren-9-one; SMER3(SMER 3); Oprea1_175199; Oprea1_783821; SCHEMBL7984580; CHEMBL3589013; ZINC27763; AOB5567; DTXSID40340952; CHEBI:131171; BDBM188214; HMS1607O01; BCP14360; 2188AH; MFCD00451458; SBB000632; STK120842; SMER3, >=98% (HPLC); AKOS000479457; MCULE-1070513713; AS-55891; ST000573; DB-073845; FT-0701471; Indeno[1,2-b]furazano[3,4-E]pyrazin-9-one; Indeno[1,2-b]furazano[3,4-E]pyrazin-9-one,; US9073941, 28; US9073941, 30; SR-01000388225; SR-01000388225-1; Q27224946; 9H-Indeno[1,2-b][1,2,5]oxadiazolo[3,4-E]pyrazin-9-one #
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Preclinical | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H4N4O2
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)C3=NC4=NON=C4N=C3C2=O
|
|||
| InChI |
1S/C11H4N4O2/c16-9-6-4-2-1-3-5(6)7-8(9)13-11-10(12-7)14-17-15-11/h1-4H
|
|||
| InChIKey |
SFSSAKVWCKFRHE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 67200-34-4
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:131171
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 2014 Jan;124(1):6-12. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.